NIFEDIPINE FIRST GENERIC APPROVAL GRANTED TO PUREPAC; EFFECTIVE DATE
• By The Pink Sheet
NIFEDIPINE FIRST GENERIC APPROVAL GRANTED TO PUREPAC; EFFECTIVE DATE of the ANDA approval, however, is delayed until an as-yet-undetermined date because of ANDA exclusivity that may be granted to another company. Purepac received approval for nifedipine 10 and 20 mg caps (Pfizer's Procardia and Miles' Adalat) on April 28. Under provisions of the Waxman/Hatch law, the first company to submit an ANDA for a generic drug and successfully challenge the innovator's patent is entitled to 180 days of marketing exclusivity, starting from either the date of its approval or the date of a court ruling of noninfringement. FDA explained in its approval letter to Purepac that an undisclosed generic firm submitted its nifedipine marketing application prior to Purepac and is currently in litigation with Pfizer over the validity of the nifedipine patent, which expires in January 1991. "Because of this litigation, the effective date of approval of your application must be delayed until a ruling by a court that the patent is invalid or will not be infringed, or the drug product which is the subject of this previously submitted application is the first commercially marketed, whichever is earlier," FDA told the generic company. The patent reportedly covers formulation of the drug. Purepac is also still in litigation with Pfizer over the nifedipine patent. Purepac's approval marks the second time that a generic firm has been delayed from entering the market by ANDA exclusivity provisions when the exclusivity holder had not yet received its ANDA approval. American Therapeutics received the first approval for a generic version of Lederle's Maxzide in November 1987, but was prevented from marketing because of an exclusivity grant to Vitarine. Vitarine subsequently received ANDA approval in December, starting off the 180-day exclusivity time clock.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.
The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.
The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.